Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Tangen wins contract re candida auris

Tangen Biosciences has been awarded a contract to develop a point-of-care device for detection of Candida auris, a “superbug” that is resistant to anti-fungal drugs and...

| By Kelley Gipson

UConn advances research re liver and COVID-19

University of Connecticut researcher Dr. George Wu recently published a paper outlining his successful experiment delivering mitochondria to liver cells. This marks the first time researchers...

| By Kelley Gipson

SpringWorks advances re myeloma, solid tumors

SpringWorks Therapeutics reports that the first patient has been dosed in a Phase 1b clinical trial evaluating the company’s investigational gamma secretase inhibitor, nirogacestat, in combination with...

| By Kelley Gipson

Guilford, Branford biotechs fight COVID-19

Federal regulators have green-lighted Guilford’s AI Therapeutics to begin a clinical trial to test if its experimental drug for non-Hodgkin lymphoma and ALS could also...

| By Kelley Gipson

BioCT welcomes new member AlloMek

AlloMek Therapeutics is a privately held company focused on developing macrocycles for treating rare diseases. AlloMek’s most advance candidate, CIP-137401, is an IND ready molecule...

| By Kelley Gipson

UConn studying obesity, pediatric hydrocephalus

Two University of Connecticut Health researchers will investigate the regulators of a cell type that plays a critical role in metabolic diseases associated with obesity....

| By Kelley Gipson

Azitra garners pediatric disease designation

Azitra reports that the FDA has granted Rare Pediatric Disease Designation to ATR-12 for the treatment of Netherton syndrome, a chronic genetic skin disease that can...

| By Kelley Gipson

BMS CEO optimistic re future of medical research

Giovanni Caforio, chairman and CEO of Bristol Myers Squibb, was recently interviewed in Fortune: “If there is any good news coming out of the coronavirus pandemic, it’s...